

In the Claims

1. (Currently amended) A ~~fusion-partner-protein~~ polypeptide of no more than 140 amino acids comprising a choline binding domain of SEQ ID NO:8, wherein a ~~and a heterologous promiscuous~~ T helper epitope from Tetanus toxin is inserted into said SEQ ID NO:8.
2. (Withdrawn) A fusion partner protein according to claim 1 wherein the choline binding domain is derived from the C terminus of LytA.
3. (Withdrawn) A fusion partner protein according to claim 2 wherein the C-LytA or derivatives comprises at least four repeats of any of SEQ ID NO: 1 to 6.
4. (Withdrawn) A fusion partner protein according to claim 1, wherein the choline binding domain is selected from the group of:
 - a) the C-terminal domain of LytA as set forth in SEQ ID NO:7;
 - b) the sequence of SEQ ID NO:8;
 - c) a peptide sequence comprising an amino acid sequence having at least 85% identity to any of SEQ ID NO:1 to 6; and
 - d) a peptide sequence comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids from the amino acid sequence of SEQ ID NO:7 or SEQ ID NO:8.
5. (Currently amended) A fusion ~~-partner-~~ protein comprising a polypeptide as claimed in claim 1 and further comprising a heterologous protein.
6. (Currently amended) A fusion protein as claimed in claim 5 wherein the heterologous protein is chemically conjugated to said polypeptide ~~the fusion partner.~~

7. (Currently amended) A fusion protein as claimed in claim 5 wherein the heterologous protein is derived from an organism selected from the following group: Human Immunodeficiency virus HIV-1, human herpes simplex viruses, cytomegalovirus, Rotavirus, Epstein Barr virus, Varicella Zoster Virus, hepatitis A virus, hepatitis C virus, hepatitis E virus, ~~from~~ Respiratory Syncytial virus, parainfluenza virus, measles virus, mumps virus, human papilloma viruses, flaviviruses, and Influenza virus, ~~from~~ Neisseria species spp., Moraxella species spp., Bordetella species spp., Mycobacterium species spp., ~~Mycobacterium M.~~ tuberculosis; Escherichia species spp., enterotoxigenic Escherichia E. coli; Salmonella species spp.; Listeria species spp.; Helicobacter species spp.; Staphylococcus species spp., Staphylococcus S. aureus, Staphylococcus S. epidermidis; Borrelia species spp.; Chlamydia species spp., Chlamydia C. trachomatis, Chlamydia C. pneumoniae; Plasmodium species spp., Plasmodium P. falciparum; Toxoplasma species spp., or Candida species spp.
8. (Currently amended) A fusion protein as claimed in claim 5 wherein the heterologous protein is selected from a tumour associated protein, an immunogenic fragment of a tumor associated protein, a ~~or~~ tissue specific protein, and an ~~or~~ immunogenic fragment of a tissue specific protein thereof.
9. (Currently amended) A fusion protein as claimed in claim 8 wherein the heterologous protein ~~or fragment thereof~~ is selected from MAGE 1, MAGE 3, MAGE 4, PRAME, BAGE, LAGE 1, LAGE 2, SAGE, HAGE, XAGE, PSA, PAP, PSCA, prostatein, P501S, HASH2, Cripto, B726, NY-BR1.1, P510, MUC-1, Prostase, STEAP, tyrosinase, telomerase, survivin, CASB616, P53, and ~~or~~ her 2 neu, or an immunogenic fragment thereof.
10. (Previously presented) A fusion protein as claimed in claim 6 further comprising an affinity tag of at least 4 histidine residues.

11. (Currently amended) A nucleic acid sequence encoding a polypeptide ~~protein~~ of claim 1.
12. (Original) An expression vector comprising a nucleic acid sequence of claim 11.
13. (Previously presented) A host cell transformed with an expression vector of claim 12.
14. (Currently amended) An immunogenic composition comprising a fusion protein ~~protein~~ as claimed in claim 5 ~~claim 4~~ and a pharmaceutically acceptable excipient.
15. (Original) An immunogenic composition as claimed in claim 14 which additionally comprises a TH-1 inducing adjuvant.
16. (Original) An immunogenic composition as claimed in claim 15 in which the TH-1 inducing adjuvant is selected from the group of adjuvants comprising: 3D-MPL, QS21, a mixture of QS21 and cholesterol, a CpG oligonucleotide or a mixture of two or more said adjuvants.
17. (Previously presented) A process for the preparation of a immunogenic composition, comprising admixing the fusion protein of claim 6 with a suitable adjuvant, diluent or other pharmaceutically acceptable carrier.
18. (Currently amended) A process for producing a polypeptide ~~fusion protein~~ of claim 1 comprising culturing a host cell comprising a vector encoding said polypeptide ~~fusion protein~~ under conditions sufficient for the production of said polypeptide ~~fusion protein~~ and recovering the polypeptide ~~fusion protein~~ from the culture medium.
19. (Currently amended) A pharmaceutical composition comprising a fusion protein ~~fusion protein~~ of claim 5 ~~claim 4~~.

20.-25. (Canceled)

26. -35. (Withdrawn)

- 36. (New) A polypeptide according to claim 1 where said T helper epitope is selected from the P2 and P30 epitopes of tetanus toxoid.
- 37. (New) A polypeptide according to claim 36 consisting of amino acid residues 5-133 of SEQ ID NO:27.
- 38. (New) A fusion protein comprising a polypeptide of claim 36 and a heterologous protein.